InsiderTrades

Form 4 for BVS Bioventus Inc.

Accepted 2024-03-25 00:00:00 ET · period of report 2024-03-21 · accession 0001578563-24-000182 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-25 2024-03-21 BVS Singleton Mark Leonard SVP, CFO M - OptEx — +18.6K 31.2K +148% —
D 2024-03-25 2024-03-22 BVS Singleton Mark Leonard SVP, CFO S - Sale+OE $5.39 -5,541 25.7K -18% -$29.9K
D 2024-03-25 2024-03-21 BVS Singleton Mark Leonard SVP, CFO M - OptEx $0.00 -18.6K 37.2K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2024-03-21 M A 18,625 — 31,206 D — — (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
2 Common Class A Common Stock 2024-03-22 S D 5,541 $5.39 25,665 D — — (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.36 to $5.43, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Restricted Stock Units 2024-03-21 M D 18,625 $0.00 37,250 D — · — to — 18,625 Class A Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F4) The original grant of 74,500 RSUs vests in four approximately equal annual installments that began on March 21, 2023.